Insider · CIK 0001228865
Leon O Moulder Jr
Files at ZLAB (Zai Lab Ltd), ZBIO (Zenas BioPharma, Inc.). First filing Nov 20, 2024, latest Oct 9, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZBIO: Zenas BioPharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Zenas BioPharma, Inc. | $770k 36,928 shares | - | +224% from low-19% from high | |
| 57Moderate | ZBIObuy Zenas BioPharma, Inc. | $718k 70,000 shares | +41% | - | |
| 39Weak | ZBIObuy Zenas BioPharma, Inc. | $149k 10,000 shares | +6% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +36,928 | $20.85 | $770k | 36,928 | Oct 9, 2025 |
| Jun 18, 2025 | ZLAB Zai Lab Ltd | AGrant or award American Depositary Shares | +10,831 | $0.00 | $0 | 72,602 | Jun 23, 2025 |
| Jun 10, 2025 | ZBIO Zenas BioPharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jun 12, 2025 |
| Dec 3, 2024 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +25,000 | $10.76 | $269k | 196,155 | Dec 4, 2024 |
| Dec 4, 2024 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +45,000 | $9.98 | $449k | 241,155 | Dec 4, 2024 |
| Nov 18, 2024 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +7,500 | $15.00 | $113k | 168,655 | Nov 20, 2024 |
| Nov 19, 2024 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +2,500 | $14.57 | $36k | 171,155 | Nov 20, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.